REFERENCES
Alexander, S.P., Christopoulos, A., Davenport, A.P., Kelly, E., Mathie, A., Peters, J.A., et al. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. Br J Pharmacol 178 Suppl 1 : S27–S156.
Amodeo, D.A., Cuevas, L., Dunn, J.T., Sweeney, J.A., and Ragozzino, M.E. (2018). The adenosine A2A receptor agonist, CGS 21680, attenuates a probabilistic reversal learning deficit and elevated grooming behavior in BTBR mice. Autism Res 11 : 223–233.
Andari, E., Duhamel, J.-R., Zalla, T., Herbrecht, E., Leboyer, M., and Sirigu, A. (2010). Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A107 : 4389–4394.
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., et al. (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism 12 : 6.
Bast, N., Poustka, L., and Freitag, C.M. (2018). The locus coeruleus-norepinephrine system as pacemaker of attention - a developmental mechanism of derailed attentional function in autism spectrum disorder. Eur J Neurosci 47 : 115–125.
Beaulieu, J.-M., and Gainetdinov, R.R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev63 : 182–217.
Bedogni, F., Cobolli Gigli, C., Pozzi, D., Rossi, R.L., Scaramuzza, L., Rossetti, G., et al. (2016). Defects During Mecp2 Null Embryonic Cortex Development Precede the Onset of Overt Neurological Symptoms. Cereb Cortex 26 : 2517–2529.
Beerepoot, P., Nazari, R., and Salahpour, A. (2017). Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies. Pharmacol Res 117 : 242–251.
Berendzen, K.M., Sharma, R., Mandujano, M.A., Wei, Y., Rogers, F.D., Simmons, T.C., et al. (2022). Oxytocin receptor is not required for social attachment in prairie voles. Neuron S0896-6273(22)01084–4.
Berger, M., Gray, J.A., and Roth, B.L. (2009). The expanded biology of serotonin. Annu Rev Med 60 : 355–366.
Berry-Kravis, E.M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 4 : 152ra127.
Bever, Y. van, Rooms, L., Laridon, A., Reyniers, E., Luijk, R. van, Scheers, S., et al. (2005). Clinical report of a pure subtelomeric 1qter deletion in a boy with mental retardation and multiple anomalies adds further evidence for a specific phenotype. Am J Med Genet A 135 : 91–95.
Beversdorf, D.Q. (2020). The Role of the Noradrenergic System in Autism Spectrum Disorders, Implications for Treatment. Semin Pediatr Neurol35 : 100834.
Blanchard, R.J., Griebel, G., Farrokhi, C., Markham, C., Yang, M., and Blanchard, D.C. (2005). AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacol Biochem Behav 80 : 189–194.
Bolognani, F., Del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., et al. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med 11 : eaat7838.
Brody, S.A., Dulawa, S.C., Conquet, F., and Geyer, M.A. (2004). Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9 : 35–41.
Campbell, N.G., Zhu, C.-B., Lindler, K.M., Yaspan, B.L., Kistner-Griffin, E., NIH ARRA Consortium, et al. (2013). Rare coding variants of the adenosine A3 receptor are increased in autism: on the trail of the serotonin transporter regulome. Mol Autism 4 : 28.
Campi, K.L., Greenberg, G.D., Kapoor, A., Ziegler, T.E., and Trainor, B.C. (2014). Sex differences in effects of dopamine D1 receptors on social withdrawal. Neuropharmacology 77 : 208–216.
Carreira, L.D., Matias, F.C., and Campos, M.G. (2022). Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders. Biomedicines 10 : 796.
Cataldo, I., Azhari, A., and Esposito, G. (2018). A Review of Oxytocin and Arginine-Vasopressin Receptors and Their Modulation of Autism Spectrum Disorder. Front Mol Neurosci 11 : 27.
Chadman, K.K., Fernandes, S., DiLiberto, E., and Feingold, R. (2019). Do animal models hold value in Autism spectrum disorder (ASD) drug discovery? Expert Opin Drug Discov 14 : 727–734.
Chana, G., Laskaris, L., Pantelis, C., Gillett, P., Testa, R., Zantomio, D., et al. (2015). Decreased expression of mGluR5 within the dorsolateral prefrontal cortex in autism and increased microglial number in mGluR5 knockout mice: Pathophysiological and neurobehavioral implications. Brain Behav Immun 49 : 197–205.
Chartoff, E.H., Marck, B.T., Matsumoto, A.M., Dorsa, D.M., and Palmiter, R.D. (2001). Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci U S A 98 : 10451–10456.
Chen, Q., Kogan, J.H., Gross, A.K., Zhou, Y., Walton, N.M., Shin, R., et al. (2012). SREB2/GPR85, a schizophrenia risk factor, negatively regulates hippocampal adult neurogenesis and neurogenesis-dependent learning and memory. Eur J Neurosci 36 : 2597–2608.
Ciruela, F., Gómez-Soler, M., Guidolin, D., Borroto-Escuela, D.O., Agnati, L.F., Fuxe, K., et al. (2011). Adenosine receptor containing oligomers: their role in the control of dopamine and glutamate neurotransmission in the brain. Biochim Biophys Acta 1808 : 1245–1255.
Coelho, J.E., Alves, P., Canas, P.M., Valadas, J.S., Shmidt, T., Batalha, V.L., et al. (2014). Overexpression of Adenosine A2A Receptors in Rats: Effects on Depression, Locomotion, and Anxiety. Front Psychiatry 5 : 67.
D’Antoni, S., Spatuzza, M., Bonaccorso, C.M., Musumeci, S.A., Ciranna, L., Nicoletti, F., et al. (2014). Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neurosci Biobehav Rev 46 Pt 2 : 228–241.
De la Cruz, O., Blekhman, R., Zhang, X., Nicolae, D., Firestein, S., and Gilad, Y. (2009). A signature of evolutionary constraint on a subset of ectopically expressed olfactory receptor genes. Mol Biol Evol 26 : 491–494.
De Nuccio, C., Bernardo, A., Ferrante, A., Pepponi, R., Martire, A., Falchi, M., et al. (2019). Adenosine A2A receptor stimulation restores cell functions and differentiation in Niemann-Pick type C-like oligodendrocytes. Sci Rep 9 : 9782.
De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha, K., Cicek, A.E., et al. (2014). Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515 : 209–215.
Dekan, Z., Kremsmayr, T., Keov, P., Godin, M., Teakle, N., Dürrauer, L., et al. (2021). Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin. Chem Sci 12 : 4057–4062.
Di Prisco, G.V., Huang, W., Buffington, S.A., Hsu, C.-C., Bonnen, P.E., Placzek, A.N., et al. (2014). Translational control of mGluR-dependent long-term depression and object-place learning by eIF2α. Nat Neurosci17 : 1073–1082.
DiCarlo, G.E., Aguilar, J.I., Matthies, H.J., Harrison, F.E., Bundschuh, K.E., West, A., et al. (2019). Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors. J Clin Invest 129 : 3407–3419.
Dumais, K.M., Bredewold, R., Mayer, T.E., and Veenema, A.H. (2013). Sex differences in oxytocin receptor binding in forebrain regions: correlations with social interest in brain region- and sex- specific ways. Horm Behav 64 : 693–701.
Dunham, J.H., Meyer, R.C., Garcia, E.L., and Hall, R.A. (2009). GPR37 surface expression enhancement via N-terminal truncation or protein-protein interactions. Biochemistry 48 : 10286–10297.
El Khamlichi, C., Reverchon, F., Hervouet-Coste, N., Robin, E., Chopin, N., Deau, E., et al. (2022). Serodolin, a β-arrestin-biased ligand of 5-HT7 receptor, attenuates pain-related behaviors. Proc Natl Acad Sci U S A 119 : e2118847119.
Elands, J., Barberis, C., and Jard, S. (1988). [3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am J Physiol 254 : E31-38.
Farook, M.F., DeCuypere, M., Hyland, K., Takumi, T., LeDoux, M.S., and Reiter, L.T. (2012). Altered serotonin, dopamine and norepinepherine levels in 15q duplication and Angelman syndrome mouse models. PLoS One7 : e43030.
Fatemi, S.H., Folsom, T.D., Kneeland, R.E., and Liesch, S.B. (2011). Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken) 294 : 1635–1645.
Fatemi, S.H., Folsom, T.D., Reutiman, T.J., and Thuras, P.D. (2009). Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum 8 : 64–69.
Ferguson, J.N., Aldag, J.M., Insel, T.R., and Young, L.J. (2001). Oxytocin in the medial amygdala is essential for social recognition in the mouse. J Neurosci 21 : 8278–8285.
Firouzabadi, N., Ghazanfari, N., Alavi Shoushtari, A., Erfani, N., Fathi, F., Bazrafkan, M., et al. (2016). Genetic Variants of Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control Study. PLoS One 11 : e0153667.
Fish, E.W., Faccidomo, S., and Miczek, K.A. (1999). Aggression heightened by alcohol or social instigation in mice: reduction by the 5-HT(1B) receptor agonist CP-94,253. Psychopharmacology (Berl)146 : 391–399.
Fisher, N.M., AlHashim, A., Buch, A.B., Badivuku, H., Samman, M.M., Weiss, K.M., et al. (2021). A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypes. JCI Insight 6 : e143324, 143324.
Fisher, N.M., Gould, R.W., Gogliotti, R.G., McDonald, A.J., Badivuku, H., Chennareddy, S., et al. (2020). Phenotypic profiling of mGlu7 knockout mice reveals new implications for neurodevelopmental disorders. Genes Brain Behav 19 : e12654.
Frantz, M.-C., Pellissier, L.P., Pflimlin, E., Loison, S., Gandía, J., Marsol, C., et al. (2018). LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. J Med Chem 61 : 8670–8692.
Froemke, R.C., and Young, L.J. (2021). Oxytocin, Neural Plasticity, and Social Behavior. Annu Rev Neurosci 44 : 359–381.
Fujita-Jimbo, E., Tanabe, Y., Yu, Z., Kojima, K., Mori, M., Li, H., et al. (2015). The association of GPR85 with PSD-95-neuroligin complex and autism spectrum disorder: a molecular analysis. Mol Autism 6 : 17.
Gabriele, S., Sacco, R., and Persico, A.M. (2014). Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol 24 : 919–929.
Gazestani, V.H., Pramparo, T., Nalabolu, S., Kellman, B.P., Murray, S., Lopez, L., et al. (2019). A perturbed gene network containing PI3K-AKT, RAS-ERK and WNT-β-catenin pathways in leukocytes is linked to ASD genetics and symptom severity. Nat Neurosci 22 : 1624–1634.
Gidaya, N.B., Lee, B.K., Burstyn, I., Michael, Y., Newschaffer, C.J., and Mortensen, E.L. (2016). In utero Exposure to β-2-Adrenergic Receptor Agonist Drugs and Risk for Autism Spectrum Disorders. Pediatrics137 : e20151316.
Gilbert, D.L., Murphy, T.K., Jankovic, J., Budman, C.L., Black, K.J., Kurlan, R.M., et al. (2018). Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord 33 : 1272–1280.
Gogliotti, R.G., Senter, R.K., Fisher, N.M., Adams, J., Zamorano, R., Walker, A.G., et al. (2017). mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Sci Transl Med 9 : eaai7459.
Gomez-Castro, F., Zappettini, S., Pressey, J.C., Silva, C.G., Russeau, M., Gervasi, N., et al. (2021). Convergence of adenosine and GABA signaling for synapse stabilization during development. Science374 : eabk2055.
Guastella, A.J., Einfeld, S.L., Gray, K.M., Rinehart, N.J., Tonge, B.J., Lambert, T.J., et al. (2010a). Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry67 : 692–694.
Guastella, A.J., Kenyon, A.R., Alvares, G.A., Carson, D.S., and Hickie, I.B. (2010b). Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans. Biol Psychiatry 67 : 1220–1222.
Guerrero, A. (2018). A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update. Curr Med Chem 25 : 3597–3612.
Hammock, E. a. D., Lim, M.M., Nair, H.P., and Young, L.J. (2005). Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior. Genes Brain Behav 4 : 289–301.
Hauser, A.S., Attwood, M.M., Rask-Andersen, M., Schiöth, H.B., and Gloriam, D.E. (2017). Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 16 : 829–842.
Hauser, A.S., Chavali, S., Masuho, I., Jahn, L.J., Martemyanov, K.A., Gloriam, D.E., et al. (2018). Pharmacogenomics of GPCR Drug Targets. Cell 172 : 41-54.e19.
Hegarty, J.P., Ferguson, B.J., Zamzow, R.M., Rohowetz, L.J., Johnson, J.D., Christ, S.E., et al. (2017). Beta-adrenergic antagonism modulates functional connectivity in the default mode network of individuals with and without autism spectrum disorder. Brain Imaging Behav 11 : 1278–1289.
Henderson, C., Wijetunge, L., Kinoshita, M.N., Shumway, M., Hammond, R.S., Postma, F.R., et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 4 : 152ra128.
Hertz, E., Terenius, L., Vukojević, V., and Svenningsson, P. (2019). GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells. Neuropharmacology 152 : 51–57.
Hiraki, Y., Okamoto, N., Ida, T., Nakata, Y., Kamada, M., Kanemura, Y., et al. (2008). Two new cases of pure 1q terminal deletion presenting with brain malformations. Am J Med Genet A 146A : 1241–1247.
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C.M., Aronowitz, B.R., et al. (2003). Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology 28 : 193–198.
Hopkins, W.D., Donaldson, Z.R., and Young, L.J. (2012). A polymorphic indel containing the RS3 microsatellite in the 5’ flanking region of the vasopressin V1a receptor gene is associated with chimpanzee (Pan troglodytes) personality. Genes Brain Behav 11 : 552–558.
Horie, K., Inoue, K., Suzuki, S., Adachi, S., Yada, S., Hirayama, T., et al. (2019). Oxytocin receptor knockout prairie voles generated by CRISPR/Cas9 editing show reduced preference for social novelty and exaggerated repetitive behaviors. Horm Behav 111 : 60–69.
Hormozdiari, F., Penn, O., Borenstein, E., and Eichler, E.E. (2015). The discovery of integrated gene networks for autism and related disorders. Genome Res 25 : 142–154.
Imai, Y., Inoue, H., Kataoka, A., Hua-Qin, W., Masuda, M., Ikeda, T., et al. (2007). Pael receptor is involved in dopamine metabolism in the nigrostriatal system. Neurosci Res 59 : 413–425.
Jacob, S., Veenstra-VanderWeele, J., Murphy, D., McCracken, J., Smith, J., Sanders, K., et al. (2022). Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry 9 : 199–210.
Jacquemont, S., Berry-Kravis, E., Hagerman, R., Raison, F. von, Gasparini, F., Apostol, G., et al. (2014). The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 231 : 1237–1250.
Jacquemont, S., Curie, A., Portes, V. des, Torrioli, M.G., Berry-Kravis, E., Hagerman, R.J., et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3 : 64ra1.
Jin, C., Kang, H., Ryu, J.R., Kim, S., Zhang, Y., Lee, Y., et al. (2018). Integrative Brain Transcriptome Analysis Reveals Region-Specific and Broad Molecular Changes in Shank3-Overexpressing Mice. Front Mol Neurosci 11 : 250.
Jing, F., Mogi, M., Sakata, A., Iwanami, J., Tsukuda, K., Ohshima, K., et al. (2012). Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab 32 : 248–255.
John, S., and Jaeggi, A.V. (2021). Oxytocin levels tend to be lower in autistic children: A meta-analysis of 31 studies. Autism 25 : 2152–2161.
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M.J., Kreutzberg, G.W., Sher, A., et al. (2000). Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20 : 4106–4114.
Jurek, B., and Neumann, I.D. (2018). The Oxytocin Receptor: From Intracellular Signaling to Behavior. Physiol Rev 98 : 1805–1908.
Kang, H.J., Kawasawa, Y.I., Cheng, F., Zhu, Y., Xu, X., Li, M., et al. (2011). Spatio-temporal transcriptome of the human brain. Nature478 : 483–489.
Khan, M.Z., and He, L. (2017). Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology (Berl) 234 : 1181–1207.
Koshimizu, T., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H., and Tanoue, A. (2012). Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 92 : 1813–1864.
Laboute, T., Gandía, J., Pellissier, L.P., Corde, Y., Rebeillard, F., Gallo, M., et al. (2020). The orphan receptor GPR88 blunts the signaling of opioid receptors and multiple striatal GPCRs. Elife 9 : e50519.
Lacivita, E., Niso, M., Mastromarino, M., Garcia Silva, A., Resch, C., Zeug, A., et al. (2021). Knowledge-Based Design of Long-Chain Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as Potential Candidates for Treatment of Autism Spectrum Disorder. ACS Chem Neurosci 12 : 1313–1327.
Lee, Y., Kim, H., Kim, J.-E., Park, J.-Y., Choi, J., Lee, J.-E., et al. (2018). Excessive D1 Dopamine Receptor Activation in the Dorsal Striatum Promotes Autistic-Like Behaviors. Mol Neurobiol 55 : 5658–5671.
León, K., Boulo, T., Musnier, A., Morales, J., Gauthier, C., Dupuy, L., et al. (2014). Activation of a GPCR leads to eIF4G phosphorylation at the 5’ cap and to IRES-dependent translation. J Mol Endocrinol52 : 373–382.
Leppanen, J., Ng, K.W., Kim, Y.-R., Tchanturia, K., and Treasure, J. (2018). Meta-analytic review of the effects of a single dose of intranasal oxytocin on threat processing in humans. J Affect Disord225 : 167–179.
Lewis, M.H., Rajpal, H., and Muehlmann, A.M. (2019). Reduction of repetitive behavior by co-administration of adenosine receptor agonists in C58 mice. Pharmacol Biochem Behav 181 : 110–116.
Li, W., and Pozzo-Miller, L. (2020). Dysfunction of the corticostriatal pathway in autism spectrum disorders. J Neurosci Res 98 : 2130–2147.
Li, X., Gardner, E.L., and Xi, Z.-X. (2008). The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats. Neuropharmacology 54 : 542–551.
Lohith, T.G., Osterweil, E.K., Fujita, M., Jenko, K.J., Bear, M.F., and Innis, R.B. (2013). Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome? Mol Autism 4 : 15.
Lozano, R., Martinez-Cerdeno, V., and Hagerman, R.J. (2015). Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder. Curr Pharm Des 21 : 4972–4979.
Lukens, J.R., and Eyo, U.B. (2022). Microglia and Neurodevelopmental Disorders. Annu Rev Neurosci 45 : 425–445.
Lüscher, C., Jan, L.Y., Stoffel, M., Malenka, R.C., and Nicoll, R.A. (1997). G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19 : 687–695.
Macdonald, K., and Macdonald, T.M. (2010). The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 18 : 1–21.
Madsen, D., Azevedo, C., Micco, I., Petersen, L.K., and Hansen, N.J.V. (2020). An overview of DNA-encoded libraries: A versatile tool for drug discovery. Prog Med Chem 59 : 181–249.
Maguire, G.A., Riley, G.D., Franklin, D.L., Maguire, M.E., Nguyen, C.T., and Brojeni, P.H. (2004). Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry 16 : 63–67.
Mahdavinasab, S.-M., Saghazadeh, A., Motamed-Gorji, N., Vaseghi, S., Mohammadi, M.-R., Alichani, R., et al. (2019). Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. Eur Child Adolesc Psychiatry 28 : 1619–1628.
Manahan-Vaughan, D., and Reymann, K.G. (1995). Regional and developmental profile of modulation of hippocampal synaptic transmission and LTP by AP4-sensitive mGluRs in vivo. Neuropharmacology 34 : 991–1001.
Manoli, D.S., and State, M.W. (2021). Autism Spectrum Disorder Genetics and the Search for Pathological Mechanisms. Am J Psychiatry 178 : 30–38.
Mantella, R.C., Vollmer, R.R., Li, X., and Amico, J.A. (2003). Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology 144 : 2291–2296.
Marazziti, D., Mandillo, S., Di Pietro, C., Golini, E., Matteoni, R., and Tocchini-Valentini, G.P. (2007). GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc Natl Acad Sci U S A 104 : 9846–9851.
Marti-Solano, M., Crilly, S.E., Malinverni, D., Munk, C., Harris, M., Pearce, A., et al. (2020). Combinatorial expression of GPCR isoforms affects signalling and drug responses. Nature 587 : 650–656.
Matsumoto, M., Straub, R.E., Marenco, S., Nicodemus, K.K., Matsumoto, S.-I., Fujikawa, A., et al. (2008). The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia. Proc Natl Acad Sci U S A 105 : 6133–6138.
McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162 : 1142–1148.
Meyer-Lindenberg, A., Kolachana, B., Gold, B., Olsh, A., Nicodemus, K.K., Mattay, V., et al. (2009). Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Mol Psychiatry 14 : 968–975.
Ming, X., Gordon, E., Kang, N., and Wagner, G.C. (2008). Use of clonidine in children with autism spectrum disorders. Brain Dev30 : 454–460.
Mishra, A., Singh, S., and Shukla, S. (2018). Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson’s disease. J Exp Neurosci 12 : 1179069518779829.
Mitsukawa, K., Yamamoto, R., Ofner, S., Nozulak, J., Pescott, O., Lukic, S., et al. (2005). A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U S A102 : 18712–18717.
Monfared, R.V., Alhassen, W., Truong, T.M., Gonzales, M.A.M., Vachirakorntong, V., Chen, S., et al. (2021). Transcriptome Profiling of Dysregulated GPCRs Reveals Overlapping Patterns across Psychiatric Disorders and Age-Disease Interactions. Cells 10 : 2967.
Mujić-Delić, A., Wit, R.H. de, Verkaar, F., and Smit, M.J. (2014). GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. Trends Pharmacol Sci 35 : 247–255.
Muller, C.L., Anacker, A.M.J., and Veenstra-VanderWeele, J. (2016). The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience 321 : 24–41.
Musnier, A., León, K., Morales, J., Reiter, E., Boulo, T., Costache, V., et al. (2012). mRNA-selective translation induced by FSH in primary Sertoli cells. Mol Endocrinol 26 : 669–680.
Nakai, N., Nagano, M., Saitow, F., Watanabe, Y., Kawamura, Y., Kawamoto, A., et al. (2017). Serotonin rebalances cortical tuning and behavior linked to autism symptoms in 15q11-13 CNV mice. Sci Adv 3 : e1603001.
Negyessy, L., and Goldman-Rakic, P.S. (2005). Subcellular localization of the dopamine D2 receptor and coexistence with the calcium-binding protein neuronal calcium sensor-1 in the primate prefrontal cortex. J Comp Neurol 488 : 464–475.
Nelson, S.B., and Valakh, V. (2015). Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. Neuron 87 : 684–698.
Nephew, B.C., and Bridges, R.S. (2008). Arginine vasopressin V1a receptor antagonist impairs maternal memory in rats. Physiol Behav95 : 182–186.
Nisar, S., Bhat, A.A., Masoodi, T., Hashem, S., Akhtar, S., Ali, T.A., et al. (2022). Genetics of glutamate and its receptors in autism spectrum disorder. Mol Psychiatry 27 : 2380–2392.
Oblak, A.L., Gibbs, T.T., and Blatt, G.J. (2010). Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem 114 : 1414–1423.
Olender, T., Jones, T.E.M., Bruford, E., and Lancet, D. (2020). A unified nomenclature for vertebrate olfactory receptors. BMC Evol Biol20 : 42.
Olender, T., Keydar, I., Pinto, J.M., Tatarskyy, P., Alkelai, A., Chien, M.-S., et al. (2016). The human olfactory transcriptome. BMC Genomics17 : 619.
O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B.P., et al. (2012). Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485 : 246–250.
Parker, K.J., Oztan, O., Libove, R.A., Mohsin, N., Karhson, D.S., Sumiyoshi, R.D., et al. (2019). A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med 11 : eaau7356.
Passoni, I., Leonzino, M., Gigliucci, V., Chini, B., and Busnelli, M. (2016). Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation. J Neuroendocrinol 28 : n/a.
Pellissier, L.P., Pujol, C.N., Becker, J. a. J., and Le Merrer, J. (2018). Delta Opioid Receptors: Learning and Motivation. Handb Exp Pharmacol 247 : 227–260.
Perry, E.K., Lee, M.L., Martin-Ruiz, C.M., Court, J.A., Volsen, S.G., Merrit, J., et al. (2001). Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 158 : 1058–1066.
Pintacuda, G., Hsu, Y.-H.H., Tsafou, K., Li, K.W., Martín, J.M., Riseman, J., et al. (2023). Protein interaction studies in human induced neurons indicate convergent biology underlying autism spectrum disorders. Cell Genomics 100250.
Poulin, B., Butcher, A., McWilliams, P., Bourgognon, J.-M., Pawlak, R., Kong, K.C., et al. (2010). The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A 107 : 9440–9445.
Pourhamzeh, M., Moravej, F.G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., et al. (2022). The Roles of Serotonin in Neuropsychiatric Disorders. Cell Mol Neurobiol 42 : 1671–1692.
Pringsheim, T., and Marras, C. (2009). Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2009 : CD006996.
Rae, M., Lemos Duarte, M., Gomes, I., Camarini, R., and Devi, L.A. (2022). Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects. Br J Pharmacol 179 : 1544–1564.
Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell 135 : 561–571.
Román, V., Adham, N., Foley, A.G., Hanratty, L., Farkas, B., Lendvai, B., et al. (2021). Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder. Psychopharmacology (Berl) 238 : 2381–2392.
Ruhrmann, S., Kissling, W., Lesch, O.-M., Schmauss, M., Seemann, U., and Philipp, M. (2007). Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 31 : 1012–1022.
Ruzzo, E.K., Pérez-Cano, L., Jung, J.-Y., Wang, L.-K., Kashef-Haghighi, D., Hartl, C., et al. (2019). Inherited and De Novo Genetic Risk for Autism Impacts Shared Networks. Cell 178 : 850-866.e26.
Sala, M., Braida, D., Lentini, D., Busnelli, M., Bulgheroni, E., Capurro, V., et al. (2011). Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 69 : 875–882.
Salomé, N., Stemmelin, J., Cohen, C., and Griebel, G. (2006). Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) 187 : 237–244.
Satterstrom, F.K., Kosmicki, J.A., Wang, J., Breen, M.S., De Rubeis, S., An, J.-Y., et al. (2020). Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell 180 : 568-584.e23.
Scerbina, T., Chatterjee, D., and Gerlai, R. (2012). Dopamine receptor antagonism disrupts social preference in zebrafish: a strain comparison study. Amino Acids 43 : 2059–2072.
Scharf, S.H., Jaeschke, G., Wettstein, J.G., and Lindemann, L. (2015). Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol 20 : 124–134.
Schlicker, E., Werner, U., Hamon, M., Gozlan, H., Nickel, B., Szelenyi, I., et al. (1992). Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents. Br J Pharmacol 105 : 732–738.
Schnider, P., Bissantz, C., Bruns, A., Dolente, C., Goetschi, E., Jakob-Roetne, R., et al. (2020). Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem 63 : 1511–1525.
Sikich, L., Kolevzon, A., King, B.H., McDougle, C.J., Sanders, K.B., Kim, S.-J., et al. (2021). Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med 385 : 1462–1473.
Silverman, J.L., Pride, M.C., Hayes, J.E., Puhger, K.R., Butler-Struben, H.M., Baker, S., et al. (2015). GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism. Neuropsychopharmacology 40 : 2228–2239.
Song, J.-M., Kang, M., Park, D.-H., Park, S., Lee, S., and Suh, Y.H. (2021). Pathogenic GRM7 Mutations Associated with Neurodevelopmental Disorders Impair Axon Outgrowth and Presynaptic Terminal Development. J Neurosci 41 : 2344–2359.
Soriano, S.G., Amaravadi, L.S., Wang, Y.F., Zhou, H., Yu, G.X., Tonra, J.R., et al. (2002). Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 125 : 59–65.
Soumier, A., Habart, M., Lio, G., Demily, C., and Sirigu, A. (2022). Differential fate between oxytocin and vasopressin cells in the developing mouse brain. IScience 25 : 103655.
Surget, A., and Belzung, C. (2008). Involvement of vasopressin in affective disorders. Eur J Pharmacol 583 : 340–349.
Szczepanska-Sadowska, E., Wsol, A., Cudnoch-Jedrzejewska, A., Czarzasta, K., and Żera, T. (2022). Multiple Aspects of Inappropriate Action of Renin-Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases. J Clin Med 11 : 908.
Terrillon, S., Durroux, T., Mouillac, B., Breit, A., Ayoub, M.A., Taulan, M., et al. (2003). Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 17 : 677–691.
Tréfier, A., Pellissier, L.P., Musnier, A., Reiter, E., Guillou, F., and Crépieux, P. (2018). G Protein-Coupled Receptors As Regulators of Localized Translation: The Forgotten Pathway? Front Endocrinol (Lausanne) 9 : 17.
Umbricht, D., Del Valle Rubido, M., Hollander, E., McCracken, J.T., Shic, F., Scahill, L., et al. (2017). A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder. Neuropsychopharmacology 42 : 1914–1923.
Varni, J.W., Handen, B.L., Corey-Lisle, P.K., Guo, Z., Manos, G., Ammerman, D.K., et al. (2012). Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clin Ther 34 : 980–992.
Vassilatis, D.K., Hohmann, J.G., Zeng, H., Li, F., Ranchalis, J.E., Mortrud, M.T., et al. (2003). The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 100 : 4903–4908.
Veenstra-VanderWeele, J., Cook, E.H., King, B.H., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2017). Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology 42 : 1390–1398.
Vilardaga, J.-P., Clark, L.J., White, A.D., Sutkeviciute, I., Lee, J.Y., and Bahar, I. (2022). Molecular Mechanisms of PTH/PTHrP class B GPCR Signaling and Pharmacological Implications. Endocr Rev bnac032.
Voineagu, I., Wang, X., Johnston, P., Lowe, J.K., Tian, Y., Horvath, S., et al. (2011). Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474 : 380–384.
Walsh, J.J., Llorach, P., Cardozo Pinto, D.F., Wenderski, W., Christoffel, D.J., Salgado, J.S., et al. (2021). Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD. Neuropsychopharmacology 46 : 2000–2010.
Walum, H., Westberg, L., Henningsson, S., Neiderhiser, J.M., Reiss, D., Igl, W., et al. (2008). Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Natl Acad Sci U S A 105 : 14153–14156.
Wei, C.J., Li, W., and Chen, J.-F. (2011). Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 1808 : 1358–1379.
Wei, D., Allsop, S., Tye, K., and Piomelli, D. (2017). Endocannabinoid Signaling in the Control of Social Behavior. Trends Neurosci 40 : 385–396.
Witt, K.G., Hetrick, S.E., Rajaram, G., Hazell, P., Taylor Salisbury, T.L., Townsend, E., et al. (2021). Pharmacological interventions for self-harm in adults. Cochrane Database Syst Rev 1 : CD013669.
Witte, A.M., Moor, M.H.M. de, Majdandžić, M., Verhees, M.W.F.T., IJzendoorn, M.H. van, and Bakermans-Kranenburg, M.J. (2022). Effects of oxytocin and vasopressin administration on human fathers’ sensitive and challenging parenting: A randomized within-subject controlled trial. Horm Behav 142 : 105175.
Xu, J., Marshall, J.J., Kraniotis, S., Nomura, T., Zhu, Y., and Contractor, A. (2021). Genetic disruption of Grm5 causes complex alterations in motor activity, anxiety and social behaviors. Behav Brain Res 411 : 113378.
Yamada, M., Miyakawa, T., Duttaroy, A., Yamanaka, A., Moriguchi, T., Makita, R., et al. (2001). Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410 : 207–212.
Yang, H.-J., Vainshtein, A., Maik-Rachline, G., and Peles, E. (2016). G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination. Nat Commun 7 : 10884.
Yoo, Y., Jung, J., Lee, Y.-N., Lee, Y., Cho, H., Na, E., et al. (2017). GABBR2 mutations determine phenotype in rett syndrome and epileptic encephalopathy. Ann Neurol 82 : 466–478.
Zeidan, J., Fombonne, E., Scorah, J., Ibrahim, A., Durkin, M.S., Saxena, S., et al. (2022). Global prevalence of autism: A systematic review update. Autism Res 15 : 778–790.
Zelena, D. (2017). Comparison of natural and artificial vasopressin deficiency: Why is the latter lethal? Russ J Genet Appl Res 7 : 243–248.
Zhan, Y., Paolicelli, R.C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., et al. (2014). Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 17 : 400–406.
Zhang, P.-W., Ishiguro, H., Ohtsuki, T., Hess, J., Carillo, F., Walther, D., et al. (2004). Human cannabinoid receptor 1: 5’ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 9 : 916–931.
Zhou, H., Wang, J., Zhang, Y., Shao, F., and Wang, W. (2020). The Role of Microglial CX3CR1 in Schizophrenia-Related Behaviors Induced by Social Isolation. Front Integr Neurosci 14 : 551676.